CG Oncology, Inc. Common stock (CGON)vsJohnson & Johnson (JNJ)
CGON
CG Oncology, Inc. Common stock
$66.74
+3.07%
HEALTHCARE · Cap: $5.70B
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2385098% more annual revenue ($96.36B vs $4.04M). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
CGON
Avoid32
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGON.
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 409.2% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
Negative free cash flow — burning cash
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Altman Z-Score. Revenue growth of 409.2% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
CGON carries more volatility with a beta of 0.70 — expect wider price swings.
CGON is growing revenue faster at 409.2% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 32/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking cancer therapies, with its lead product, CG0070, an innovative oncolytic virus therapy targeting non-muscle invasive bladder cancer. The company is poised to address significant unmet medical needs in oncology, underscoring its potential to improve patient outcomes and reshape treatment approaches. As CG Oncology advances through clinical trials and critical regulatory milestones, it leverages its proprietary technology platform to distinguish itself in the competitive oncology sector. This strategic emphasis on pioneering therapeutic options presents an attractive opportunity for institutional investors interested in advancements that could significantly impact cancer care.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?